The article was a bit light on details, but it's always exciting to see genetics-driven research (I am quite biased in this regard). I believe [1] is the compou

The article was a bit light on details, but it's always exciting to see genetics-driven research (I am quite biased in this regard). I believe [1] is the compound they were discussing. I looked for trials with this compound on clinicaltrials.gov but found none. At this point I suspect that the NYT article conflated the HDM2 inhibitor with compound AT-406 [2], but I don't know (and this is well outside of my field). [1] = http://www.ascenta.com/development/index.php#hdm2 http://www.ascenta.com/development/index.php#hdm2 [2] = http://www.ascenta.com/development/index.php#at406 http://www.ascenta.com/development/index.php#at406